Abstract
Evaluation of the potential of a drug candidate to inhibit or inactivate cytochrome P450 (CYP) enzymes remains an important part of pharmaceutical drug Discovery and Development programs. CYP enzymes are considered to be one of the most important enzyme families involved in the metabolic clearance of the vast majority of prescribed drugs. Clinical drug-drug interactions (DDI) involving inhibition or time-dependent inactivation of these enzymes can result in dangerous side effects resulting from reduced clearance/increased exposure of the drug being affected (the ‘victim’ drug). In this regard, pharmaceutical companies have become quite vigilant in mitigating CYP inhibition/inactivation liabilities of drug candidates early in Discovery including continued risk assessment throughout Development. In this review, common strategies and decision making processes for the assessment of DDI risk in the different stages of pharmaceutical development are discussed. In addition, in vitro study designs, analysis, and interpretation of CYP inhibition and inactivation data are described in stage appropriate context. The in vitro tools and knowledge available now enable the Discovery Chemist to place the potential CYP DDI liability of a drug candidate into perspective and to aid in the optimization of chemical drug design to further mitigate this risk.
Keywords: CYP, Cytochrome P450, drug-drug interaction, inactivation, inhibition, time-dependent inactivation
Current Topics in Medicinal Chemistry
Title: Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development
Volume: 11 Issue: 4
Author(s): David O. Nettleton and Heidi J. Einolf
Affiliation:
Keywords: CYP, Cytochrome P450, drug-drug interaction, inactivation, inhibition, time-dependent inactivation
Abstract: Evaluation of the potential of a drug candidate to inhibit or inactivate cytochrome P450 (CYP) enzymes remains an important part of pharmaceutical drug Discovery and Development programs. CYP enzymes are considered to be one of the most important enzyme families involved in the metabolic clearance of the vast majority of prescribed drugs. Clinical drug-drug interactions (DDI) involving inhibition or time-dependent inactivation of these enzymes can result in dangerous side effects resulting from reduced clearance/increased exposure of the drug being affected (the ‘victim’ drug). In this regard, pharmaceutical companies have become quite vigilant in mitigating CYP inhibition/inactivation liabilities of drug candidates early in Discovery including continued risk assessment throughout Development. In this review, common strategies and decision making processes for the assessment of DDI risk in the different stages of pharmaceutical development are discussed. In addition, in vitro study designs, analysis, and interpretation of CYP inhibition and inactivation data are described in stage appropriate context. The in vitro tools and knowledge available now enable the Discovery Chemist to place the potential CYP DDI liability of a drug candidate into perspective and to aid in the optimization of chemical drug design to further mitigate this risk.
Export Options
About this article
Cite this article as:
O. Nettleton David and J. Einolf Heidi, Assessment of Cytochrome P450 Enzyme Inhibition and Inactivation in Drug Discovery and Development, Current Topics in Medicinal Chemistry 2011; 11 (4) . https://dx.doi.org/10.2174/156802611794480882
DOI https://dx.doi.org/10.2174/156802611794480882 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Discovery of Selective and Non-Selective 5-HT1D Receptor Ligands
Current Topics in Medicinal Chemistry The Developing Utility of Zebrafish Models for Cognitive Enhancers Research
Current Neuropharmacology Molecular Rationales for Signal Transduction Therapy and Chemoprevention of BRCA1-Related Breast and Ovarian Tumours
Current Signal Transduction Therapy Cucurbitacin E, An Experimental Lead Triterpenoid with Anticancer, Immunomodulatory and Novel Effects Against Degenerative Diseases. A Mini-Review
Current Topics in Medicinal Chemistry Targeting Wnt Signaling through Small molecules in Governing Stem Cell Fate and Diseases
Endocrine, Metabolic & Immune Disorders - Drug Targets The Relationship of Developmental Changes in White Matter to the Onset of Psychosis
Current Pharmaceutical Design Chronic Stress and Alzheimers Disease-Like Pathogenesis in a Rat Model: Prevention by Nicotine
Current Neuropharmacology Recent Advances in Metabolic Profiling and Imaging of Prostate Cancer
Current Metabolomics Iron Chelators as Potential Therapeutic Agents for Parkinsons Disease
Current Bioactive Compounds Evaluation of the Ionic Strength in the Preparation of Nanoparticles based on Chitosan
Drug Delivery Letters Editorial [Hot Topic: Alzheimer Drug Design Based on the Amyloid Hypothesis (Executive Editors: D. Munoz-Torrero and P. Camps)]
Current Pharmaceutical Design Dysiherbaine: A New Generation of Excitatory Amino Acids of Marine Origin
Central Nervous System Agents in Medicinal Chemistry Patented Herbal Formulations and their Therapeutic Applications
Recent Patents on Drug Delivery & Formulation Treating COPD in Older and Oldest Old Patients
Current Pharmaceutical Design Carnosine and Carnosine-Related Antioxidants: A Review
Current Medicinal Chemistry Importance of Oxidative Damage on the Electron Transport Chain for the Rational Use of Mitochondria-Targeted Antioxidants
Mini-Reviews in Medicinal Chemistry Perspective Design of Chalcones for the Management of CNS Disorders: A Mini-Review
CNS & Neurological Disorders - Drug Targets Oxytocin as a Potential Adjuvant Against COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Human Tooth Germ Stem Cells Preserve Neuro-Protective Effects after Long-Term Cryo-Preservation
Current Neurovascular Research 5HT1F- and 5HT7-Receptor Agonists for the Treatment of Migraines
CNS & Neurological Disorders - Drug Targets